Vaccines for the prevention of diarrhea due to cholera, shigella, ETEC and rotavirus

BMC Public Health

Volumn 13, Issue SUPPL.3, 2013, Pages

  Das, Jai K ^a   Tripathi, Anjali ^b   Ali, Anum ^a   Hassan, Amman ^a   Dojosoeandy, Chesarahima ^b   Bhutta, Zulfiqar A ^a,b  

^a AGA KHAN UNIVERSITY   (Pakistan)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE; CHOLERA VACCINE; SHIGELLA VACCINE; VIRUS VACCINE;

CHILD; CHOLERA; COMORBIDITY; DIARRHEA; DYSENTERY; DYSENTERY, BACILLARY; ESCHERICHIA COLI INFECTIONS; HUMAN; IMMUNIZATION; INFANT; MALE; PRESCHOOL CHILD; ROTAVIRUS INFECTIONS;

BACTERIAL VACCINES; CHILD; CHILD, PRESCHOOL; CHOLERA; CHOLERA VACCINES; COMORBIDITY; DIARRHEA; DYSENTERY; DYSENTERY, BACILLARY; ESCHERICHIA COLI INFECTIONS; HUMANS; IMMUNIZATION SCHEDULE; INFANT; MALE; ROTAVIRUS INFECTIONS; SHIGELLA VACCINES; VIRAL VACCINES;

EID: 84884410335     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/1471-2458-13-S3-S11     Document Type: Review

References (67)

1. Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. Liu L, Johnson HL, Cousens S, Perin J, Scott S, Lawn JE, Rudan I, Campbell H, Cibulskis R, Li M, Mathers C, Black RE, Child Health Epidemiology Reference Group of WHO and UNICEF, Lancet 2012 379 2151 2161 10.1016/S0140-6736(12)60560-1 22579125
2. Diarrhoeal Diseases (Updated February 2009). World Health Organization, Initiative for Vaccine Research (IVR) Accessed from http://www.who.int/vaccine- research/diseases/diarrhoeal/en/index6.html
3. Frequency of serovars and antimicrobial resistance in Shigella spp. from Brazil. Peirano G, Souza FS, Rodrigues DP, Memorias do Instituto Oswaldo Cruz 2006 101 3 245 250 10.1590/S0074-02762006000300003 23928859 (Pubitemid 43962008)
4. Prevalence of enterotoxigenic Escherichia coli-associated diarrhoea and carrier state in the developing world. Wenneras C, Erling V, J Health Popul Nutr 2004 22 4 370 382 15663170 (Pubitemid 40104097)
5. Effectiveness of mass oral cholera vaccination in Beira, Mozambique. Lucas MES, Deen JL, Von Seidlein L, Wang XY, Ampuero J, Puri M, Ali M, Ansaruzzaman M, Amos J, Macuamule A, New England Journal of Medicine 2005 352 8 757 767 10.1056/NEJMoa043323 15728808 (Pubitemid 40271170)
6. Field trial of a locally produced, killed, oral cholera vaccine in Vietnam. Trach DD, Clemens JD, Ke NT, Thuy HT, Son ND, Canh DG, Hang PVD, Rao MR, Lancet 1997 349 9047 231 235 10.1016/S0140-6736(96)06107-7 9014909 (Pubitemid 27050988)
7. Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis. Ali M, Emch M, von Seidlein L, Yunus M, Sack DA, Rao M, Holmgren J, Clemens JD, Lancet 2005 366 9479 44 49 10.1016/S0140-6736(05)66550-6 15993232 (Pubitemid 40956529)
8. Controlling endemic cholera with oral vaccines. Longini IM Jr, Nizam A, Ali M, Yunus M, Shenvi N, Clemens JD, PLoS medicine 2007 4 11 336 10.1371/journal.pmed.0040336 18044983 (Pubitemid 350220530)
9. Studies on vaccination against bacillary dysentery. Mel DM, Arsic BL, Nikolic BD, Radovanic ML, Bull WHO 1968 39 375 380 5303905
10. Studies on Vaccination against Bacillary Dysentery. Terzin AL, Vuksic CL, Bull Wld Hlth Org 1965 32 637 645
11. Cross-reactivity of Shigella flexneri serotype 2a O antigen antibodies following immunization or infection. Van De Verg LL, Bendiuk NO, Kotloff K, Marsh MM, Ruckert JL, Puryear JL, Taylor DN, Hartman AB, Vaccine 1996 14 11 1062 1068 10.1016/0264-410X(96)00006-0 8879103 (Pubitemid 26281295)
12. Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. Kotloff KL, Winickoff JP, Ivanoff B, Clemens JD, Swerdlow DL, Sansonetti PJ, Adak GK, Levine MM, Bulletin of the World Health Organization 1999 77 8 651 666 10516787 (Pubitemid 29446617)
13. Strategy for cross-protection among Shigella flexneri serotypes. Noriega FR, Liao FM, Maneval DR, Ren S, Formal SB, Levine MM, Infection and immunity 1999 67 2 782 788 9916090 (Pubitemid 29059218)
14. Broadly Protective Shigella Vaccine Based on Type III Secretion Apparatus Proteins. Martinez-Becerra FJ, Kissmann JM, Diaz-McNair J, Choudhari SP, Quick AM, Mellado-Sanchez G, Clements JD, Pasetti MF, Picking WL, Infection and immunity 2012 80 3 1222 1231 10.1128/IAI.06174-11 22202122
15. Part III. Analysis of data gaps pertaining to enterotoxigenic Escherichia coli infections in low and medium human development index countries, 1984-2005. Gupta SK, Keck J, Ram PK, Crump JA, Miller MA, Mintz ED, Epidemiology and infection 2008 136 6 721 738 17686197 (Pubitemid 351524008)
16. Disease burden due to enterotoxigenic Escherichia coli in the first 2 years of life in an urban community in Bangladesh. Qadri F, Saha A, Ahmed T, Al Tarique A, Begum YA, Svennerholm AM, Infect Immun 2007 75 8 3961 3968 10.1128/IAI.00459-07 17548483 (Pubitemid 47206294)
17. High disease burden of diarrhea due to enterotoxigenic Escherichia coli among rural Egyptian infants and young children. Rao MR, Abu-Elyazeed R, Savarino SJ, Naficy AB, Wierzba TF, Abdel-Messih I, Shaheen H, Frenck RW Jr., Svennerholm AM, Clemens JD, J Clin Microbiol 2003 41 10 4862 4864 10.1128/JCM.41.10.4862-4864.2003 14532244 (Pubitemid 37259818)
18. Progress and hurdles in the development of vaccines against enterotoxigenic Escherichia coli in humans. Zhang W, Sack DA, Expert Review of Vaccines 2012 11 6 677 694 10.1586/erv.12.37 22873126
19. Vaccines against enterotoxigenic Escherichia coli. Svennerholm AM, Tobias J, Expert Rev Vaccines 2008 7 6 795 804 10.1586/14760584.7.6.795 18665777
20. Effect of human rotavirus vaccine on severe diarrhea in African infants. Madhi SA, Cunliffe NA, Steele D, Witte D, Kirsten M, Louw C, Ngwira B, Victor JC, Gillard PH, Cheuvart BB, Han HH, Neuzil KM, N Engl J Med 2010 362 4 289 298 10.1056/NEJMoa0904797 20107214
21. The effect of rotavirus vaccine on diarrhoea mortality. Munos MK, Walker CLF, Black RE, International journal of epidemiology 2010 39 suppl 1 56 i62 20348127
22. Standards for CHERG reviews of intervention effects on child survival. Walker N, Fischer-Walker C, Bryce J, Bahl R, Cousens S, International journal of epidemiology 2010 39 suppl 1 21 i31 20348122
23. Enhanced immunogenicity of an oral inactivated cholera vaccine in infants in Bangladesh obtained by zinc supplementation and by temporary withholding breast-feeding. Ahmed T, Svennerholm AM, Tarique AA, Sultana GNN, Qadri F, Vaccine 2009 27 9 1433 1439 10.1016/j.vaccine.2008.12.036 19146904
24. Safety and immunogenicity of oral killed whole cell recombinant B subunit cholera vaccine in Barranquilla, Colombia. Concha A, Giraldo A, Castaneda E, Martinez M, Hoz Fdl, Rivas F, et al. Bulletin of the Pan American Health Organization 1995 29 4 312 321 8605522
25. Palatability, reactogenicity and immunogenicity of engineered live oral cholera vaccine CVD 103-HgR in Chilean infants and toddlers. Lagos R, San Martin O, Wasserman SS, Prado V, Losonsky GA, Bustamante C, Levine MM, Pediatr Infect Dis J 1999 18 7 624 630 10.1097/00006454-199907000-00011 10440439 (Pubitemid 29350330)
26. Private demand for cholera vaccines in Beira, Mozambique. Lucas MES, Jeuland M, Deen J, Lazaro N, MacMahon M, Nyamete A, Barreto A, von Seidlein L, Cumbane A, Songane FF, Vaccine 2007 25 14 2599 2609 10.1016/j.vaccine.2006.12. 027 17258844 (Pubitemid 46400934)
27. Evaluation of a probiotics, Bifidobacterium breve BBG-01, for enhancement of immunogenicity of an oral inactivated cholera vaccine and safety: A randomized, double-blind, placebo-controlled trial in Bangladeshi children under 5 years of age. Matsuda F, Chowdhury MI, Saha A, Asahara T, Nomoto K, Tarique AA, Ahmed T, Nishibuchi M, Cravioto A, Qadri F, Vaccine 2011 29 10 1855 1858 10.1016/j.vaccine.2010.12.133 21236234
28. Peru-15, a live attenuated oral cholera vaccine, is safe and immunogenic in Bangladeshi toddlers and infants. Qadri F, Chowdhury MI, Faruque SM, Salam MA, Ahmed T, Begum YA, Saha A, Al Tarique A, Seidlein LV, Park E, Vaccine 2007 25 2 231 238 10.1016/j.vaccine.2006.08.031 16996172 (Pubitemid 44856084)
29. Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area. Richie EE, Punjabi NH, Sidharta YY, Peetosutan KK, Sukandar MM, Wasserman SS, Lesmana MM, Wangsasaputra FF, Pandam SS, Levine MM, et al. Vaccine 2000 18 22 2399 2410 10.1016/S0264-410X(00)00006-2 10738097 (Pubitemid 30156811)
30. Safety, immunogenicity, and transmissibility of single-dose live oral cholera vaccine strain CVD 103-HgR in 24- to 59-month-old Indonesian children. Simanjuntak CH, O'Hanley P, Punjabi NH, Noriega F, Pazzaglia G, Dykstra P, Kay B, Suharyono, Budiarso A, Rifai AR, et al. J Infect Dis 1993 168 5 1169 1176 10.1093/infdis/168.5.1169 8228350 (Pubitemid 23317131)
31. Safety, immunogenicity, and lot stability of the whole cell/recombinant B subunit (WC/rCTB) cholera vaccine in Peruvian adults and children. Taylor DN, Cardenas V, Perez J, Puga R, Svennerholm AM, The American journal of tropical medicine and hygiene 1999 61 6 869 10674661
32. Field trial of inactivated oral cholera vaccines in Bangladesh: results from 5 years of follow-up. Van Loon FPL, Clemens JD, Chakraborty J, Rao MR, Kay BA, Sack DA, Yunus M, Ali M, Svennerholm AM, Holmgren J, Vaccine 1996 14 2 162 166 10.1016/0264-410X(95)00122-H 8852414 (Pubitemid 26072863)
33. Efficacy of a low-cost, inactivated whole-cell oral cholera vaccine: results from 3 years of follow-up of a randomized, controlled trial. Sur D, Kanungo S, Sah B, Manna B, Ali M, Paisley AM, Niyogi SK, Park JK, Sarkar B, Puri MK, et al. PLoS Negl Trop Dis 2011 5 10 1289 10.1371/journal.pntd.0001289 22028938
34. Safety and immunogenicity of Shigella sonnei and Shigella flexneri 2a O-specific polysaccharide conjugates in children. Ashkenazi S, Passwell JH, Harlev E, Miron D, Dagan R, Farzan N, Ramon R, Majadly F, Bryla DA, Karpas AB, et al. J Infect Dis 1999 179 6 1565 1568 10.1086/314759 10228084 (Pubitemid 29246612)
35. Shigellosis in custodial institutions. 3. Prospective clinical and bacteriologic surveillance of children vaccinated with oral attenuated shigella vaccines. Levine MM, Gangarosa EJ, Werner M, Morris GK, J Pediatr 1974 84 6 803 806 10.1016/S0022-3476(74)80751-1 4596999
36. Immune responses in Vietnamese children after a single dose of the auxotrophic, live Shigella flexneri Y vaccine strain SFL124. Li A, Cam PD, Islam D, Minh NB, Huan PT, Rong ZC, Karlsson K, Lindberg G, Lindberg AA, J Infect 1994 28 1 11 23 10.1016/S0163-4453(94)94006-1 8163828 (Pubitemid 24050411)
37. Shigella flexneri 2a and sonnei I vaccine with two attenuating markers: construction, tolerability and immunogenicity in 143 children aged 3-17 years. Linde K, Randhagen B, Beer J, Dentchev V, Marinova S, Vassilev T, Bratoyeva M, Vaccine 1993 11 2 197 199 10.1016/0264-410X(93)90017-R 8438618 (Pubitemid 23031507)
38. Studies on vaccination against bacillary dysentery. 6. Protection of children by oral immunization with streptomycin-dependent Shigella strains. Mel D, Gangarosa EJ, Radovanovic ML, Arsic BL, Litvinjenko S, Bull World Health Organ 1971 45 4 457 464 4948417
39. Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old children. Passwell JH, Ashkenazi S, Harlev E, Miron D, Ramon R, Farzam N, Lerner-Geva L, Levi Y, Chu C, Shiloach J, et al. Pediatr Infect Dis J 2003 22 8 701 706 10.1097/01.inf.0000078156.03697.a5 12913770 (Pubitemid 36999646)
40. Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1-4-year-old Israeli children. Passwell JH, Ashkenzi S, Banet-Levi Y, Ramon-Saraf R, Farzam N, Lerner-Geva L, Even-Nir H, Yerushalmi B, Chu C, Shiloach J, et al. Vaccine 2010 28 10 2231 2235 10.1016/j.vaccine.2009.12.050 20056180
41. Safety, dose, immunogenicity, and transmissibility of an oral live attenuated Shigella flexneri 2a vaccine candidate (SC602) among healthy adults and school children in Matlab, Bangladesh. Rahman KM, Arifeen SE, Zaman K, Rahman M, Raqib R, Yunus M, Begum N, Islam MS, Sohel BM, Venkatesan M, et al. Vaccine 2011 29 6 1347 1354 10.1016/j.vaccine.2010.10.035 21040694
42. Induction of systemic antifimbria and antitoxin antibody responses in Egyptian children and adults by an oral, killed enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine. Hall ER, Wierzba TF, Ahren C, Rao MR, Bassily S, Francis W, Girgis FY, Safwat M, Lee YJ, Svennerholm AM, et al. Infect Immun 2001 69 5 2853 2857 10.1128/IAI.69.5.2853-2857.2001 11292698 (Pubitemid 32332174)
43. Homologous and cross-reactive immune responses to enterotoxigenic Escherichia coli colonization factors in Bangladeshi children. Qadri F, Ahmed F, Ahmed T, Svennerholm AM, Infect Immun 2006 74 8 4512 4518 10.1128/IAI.00474-06 16861637 (Pubitemid 44157237)
44. Safety and immunogenicity of an oral, inactivated enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Bangladeshi children 18-36 months of age. Qadri F, Ahmed T, Ahmed F, Bradley Sack R, Sack DA, Svennerholm AM, Vaccine 2003 21 19-20 2394 2403 10.1016/S0264-410X(03)00077-X 12744870 (Pubitemid 36564830)
45. Safety and immunogenicity of an oral, inactivated enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Bangladeshi adults and children. Qadri F, Wenneras C, Ahmed F, Asaduzzaman M, Saha D, Albert MJ, Sack RB, Svennerholm A, Vaccine 2000 18 24 2704 2712 10.1016/S0264-410X(00)00056-6 10781858 (Pubitemid 30211579)
46. Oral, inactivated, whole cell enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine: results of the initial evaluation in children. PRIDE Study Group. Savarino SJ, Hall ER, Bassily S, Brown FM, Youssef F, Wierzba TF, Peruski L, El-Masry NA, Safwat M, Rao M, et al. J Infect Dis 1999 179 1 107 114 10.1086/314543 9841829 (Pubitemid 29028345)
47. Introductory evaluation of an oral, killed whole cell enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Egyptian infants. Savarino SJ, Hall ER, Bassily S, Wierzba TF, Youssef FG, Peruski LF Jr., Abu-Elyazeed R, Rao M, Francis WM, El Mohamady H, et al. Pediatr Infect Dis J 2002 21 4 322 330 10.1097/00006454-200204000-00012 12075764 (Pubitemid 34326871)
48. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Armah GE, Sow SO, Breiman RF, Dallas MJ, Tapia MD, Feikin DR, Binka FN, Steele AD, Laserson KF, Ansah NA, et al. Lancet 2010 376 9741 606 614 10.1016/S0140-6736(10)60889-6 20692030
49. Effect of human rotavirus vaccine on severe diarrhea in African infants. Madhi SA, Cunliffe NA, Steele D, Witte D, Kirsten M, Louw C, Ngwira B, Victor JC, Gillard PH, Cheuvart BB, et al. N Engl J Med 2010 362 4 289 298 10.1056/NEJMoa0904797 20107214
50. Safety and efficacy of human rotavirus vaccine during the first 2 years of life in Asian infants: randomised, double-blind, controlled study. Phua KB, Lim FS, Lau YL, Nelson EA, Huang LM, Quak SH, Lee BW, Teoh YL, Tang H, Boudville I, et al. Vaccine 2009 27 43 5936 5941 10.1016/j.vaccine.2009.07.098 19679216
51. Efficacy of the pentavalent rotavirus vaccine, RotaTeq(R), in Finnish infants up to 3 years of age: the Finnish Extension Study. Vesikari T, Karvonen A, Ferrante SA, Ciarlet M, Eur J Pediatr 2010 169 11 1379 1386 10.1007/s00431-010-1242-3 20559656
52. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Zaman K, Dang DA, Victor JC, Shin S, Yunus M, Dallas MJ, Podder G, Vu DT, Le TP, Luby SP, et al. Lancet 2010 376 9741 615 623 10.1016/S0140-6736(10)60755-6 20692031
53. Global, regional, and national causes of child mortality in 2008: a systematic analysis. Black RE, Cousens S, Johnson HL, Lawn JE, Rudan I, Bassani DG, Jha P, Campbell H, Walker CF, Cibulskis R, et al. Lancet 2010 375 9730 1969 1987 10.1016/S0140-6736(10)60549-1 20466419
54. Magnitude and impact of diarrheal diseases. Guerrant RL, Kosek M, Moore S, Lorntz B, Brantley R, Lima AAM, Archives of medical research 2002 33 4 351 355 10.1016/S0188-4409(02)00379-X 12234524 (Pubitemid 35299555)
55. Immunity to enterotoxigenic Escherichia coli. Levine M, Nalin D, Hoover D, Bergquist E, Hornick R, Young C, Infect Immun 1979 23 729 736 378834 (Pubitemid 9138978)
56. Protection from natural infections with enterotoxigenic Escherichia coli: longitudinal study. Steinsland H, Valentiner-Branth P, Gjessing H, Aaby P, Molbak K, Sommerfelt H, Lancet 2003 362 9380 286 291 10.1016/S0140-6736(03) 13971-2 12892959 (Pubitemid 36936840)
57. High disease burden of diarrhea due to enterotoxigenic Escherichia coli among rural Egyptian infants and young children. Rao M, Abu-Elyazeed R, Savarino S, Naficy A, Wierzba T, Abdel-Messih I, et al. J Clin Microbiol 2003 41 4862 4864 10.1128/JCM.41.10.4862-4864.2003 14532244 (Pubitemid 37259818)
58. Analysis of strategies to successfully vaccinate infants in developing countries against enterotoxigenic E. coli (ETEC) disease. Walker RI, Steele D, Aguado T
59. From cholera to enterotoxigenic Escherichia coli (ETEC) vaccine development. Svennerholm A-M, The Indian journal of medical research 2011 133 2 188 194 21415493
60. Enteric vaccines for the developing world: a challenge for mucosal immunology. Czerkinsky C, Holmgren J, Mucosal Immunology 2009 2 4 284 287 10.1038/mi.2009.22 19421181
61. Determinants of responses to oral vaccines in developing countries. Sack DA, Qadri F, Svennerholm A, Annales Nestle, English Ed 2008 66 2 71 79 10.1159/000129624 (Pubitemid 352009476)
62. Vitamin A supplementation for preventing morbidity and mortality in children from 6 months to 5 years of age. Imdad A, Herzer K, Mayo-Wilson E, Yakoob MY, Bhutta ZA, Cochrane Database Syst Rev 2010 12 D008524 10.1002/14651858.CD008524.pub2 21154399
63. How can we achieve and maintain high-quality performance of health workers in low-resource settings? Rowe AK, de Savigny D, Lanata CF, Victora CG, Lancet 2005 366 9490 1026 1035 10.1016/S0140-6736(05)67028-6 16168785 (Pubitemid 41323038)
64. Directing diarrhoeal disease research towards disease-burden reduction. Kosek M, Lanata CF, Black RE, Walker DG, Snyder JD, Salam MA, Mahalanabis D, Fontaine O, Bhutta ZA, Bhatnagar S, et al. J Health Popul Nutr 2009 27 3 319 331 19507747
65. Evaluation of vaccines against enteric infections: a clinical and public health research agenda for developing countries. Clemens J, Philos Trans R Soc Lond B Biol Sci 2011 366 2799 2805 10.1098/rstb.2011.0033 21893543
66. Broadly protective Shigella vaccine based on type III secretion apparatus proteins. Martinez-Becerra FJ, Kissmann JM, Diaz-McNair J, Choudhari SP, Quick AM, Mellado-Sanchez G, Clements JD, Pasetti MF, Picking WL, Infect Immun 2012 80 3 1222 1231 10.1128/IAI.06174-11 22202122
67. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Patriarca PA, Wright PF, John TJ, Rev Infect Dis 1991 13 5 926 939 10.1093/clinids/13.5.926 1660184